40 patents
Utility
Variant forms of urate oxidase and use thereof
10 Oct 23
Genetically modified proteins with uricolytic activity are described.
Jacob Hartman, Simona Mendelovitz
Filed: 19 Apr 22
Utility
Methods of Treating Gout
28 Sep 23
The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase in a shortened infusion period less than 120 minutes and a shortened infusion volume of less than 250 mL.
Paul Michael PELOSO, Brian David LAMOREAUX, Swarnendra K. VERMA
Filed: 10 Aug 21
Utility
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
10 Aug 23
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided.
Theresa ROSARIO-JANSEN, David Erick WRIGHT
Filed: 1 Feb 23
Utility
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
2 May 23
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided.
Theresa Rosario-Jansen, David Erick Wright
Filed: 29 Sep 20
Utility
Combination Therapies of Prednisone and Uricase Molecules and Uses Thereof
16 Mar 23
Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and/or delaying infusion reactions.
Jeffrey D. KENT, Brian LAMOREAUX
Filed: 10 Nov 17
Utility
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
7 Mar 23
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided.
Theresa Rosario-Jansen, David Erick Wright
Filed: 21 Sep 22
Utility
Variant Forms of Urate Oxidase and Use Thereof
2 Feb 23
Genetically modified proteins with uricolytic activity are described.
Jacob HARTMAN, Simona MENDELOVITZ
Filed: 19 Apr 22
Utility
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
26 Jan 23
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided.
Theresa Rosario-Jansen, David Erick Wright
Filed: 21 Sep 22
Utility
ADO-resistant cysteamine analogs and uses thereof
22 Nov 22
The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
Filed: 1 Feb 21
Utility
Variant forms of urate oxidase and use thereof
31 May 22
Genetically modified proteins with uricolytic activity are described.
Jacob Hartman, Simona Mendelovitz
Filed: 24 Jun 20
Utility
Topical Use of Levofloxacin for Reducing Lung Inflammation
17 Mar 22
The present invention relates to methods and compositions for the treatment of pulmonary inflammation.
Michael N. DUDLEY, Ruslan Y. TSIVKOVSKI, David C. GRIFFITH, Olga RODNY
Filed: 26 Apr 21
Utility
Ado-resistant Cysteamine Analogs and Uses Thereof
27 Jan 22
The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
Filed: 1 Feb 21
Utility
Methods for the Treatment of Thyroid Eye Disease
16 Sep 21
The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
David MADDEN, Kathleen GABRIEL, Guido MAGNI, Richard WOODWARD
Filed: 10 Dec 20
Utility
Methods for the Treatment of Scleroderma and Related Conditions
19 Aug 21
Provided herein are antibodies against insulin-like growth factor 1 receptor (IGF-1R) and their use in methods of treatment of, and achievement of clinical outcomes in, scleroderma and forms thereof, including diffuse cutaneous systemic sclerosis.
Elizabeth THOMPSON, Srini RAMANATHAN
Filed: 4 Feb 21
Utility
Methods for the Treatment of Thyroid Eye Disease
19 Aug 21
Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
Jeffrey W. SHERMAN, Dennis A. BENNETT, Srini RAMANATHAN, Yan XIN, Elizabeth THOMPSON, Elizabeth O'NEILL
Filed: 3 Mar 21
Utility
Delayed release cysteamine bead formulation, and methods of making and using same
17 Aug 21
An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
Kathlene Powell, Ramesh Muttavarapu, Ranjan Dohil
Filed: 12 Dec 18
Utility
Use of Aerosolized Levofloxacin for Treating Cystic Fibrosis
29 Jul 21
Methods for treating cystic fibrosis.
Jeffery S. LOUTIT, Elizabeth E. MORGAN, Michael N. DUDLEY, David C. GRIFFITH, Olga LOMOVSKAYA
Filed: 28 Aug 20
Utility
Topical use of levofloxacin for reducing lung inflammation
1 Jun 21
The present invention relates to methods and compositions for the treatment of pulmonary inflammation.
Michael N. Dudley, Ruslan Y. Tsivkovski, David C. Griffith, Olga Rodny
Filed: 11 Oct 17
Utility
Procedure for the preparation of 4-phenyl butyrate and uses thereof
25 May 21
Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric.
Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
Filed: 7 May 19
Utility
Aerosol Fluoroquinolone Formulations for Improved Pharmacokinetics
29 Apr 21
The present invention relates to the field of antimicrobial agents.
David C. GRIFFITH, Michael N. DUDLEY, Mark W. SURBER, Keith A. BOSTIAN, Olga RODNY
Filed: 16 Jun 20